Skip to main content

Table 1 Antimicrobial susceptibility ofNeisseria gonorrhoeaeisolates (n=193) from Belarus, 2010–2013

From: Antimicrobial susceptibility/resistance and NG-MAST characterisation of Neisseria gonorrhoeae in Belarus, Eastern Europe, 2010–2013

Antimicrobial

MIC50/

Susceptible (%)

Intermediate susceptible (%)

Resistant (%)

MIC90/

2010-2011

2012

2013

2010-2011

2012

2013

2010-2011

2012

2013

MIC range

(n=78)a

(n=75)

(n=40)

(n=78)a

(n=75)

(n=40)

(n=78)a

(n=75)

(n=40)

(mg/L)

Penicillin Gb

0.032/1/

-

88

78

-

5

10

-

7

13

0.008-2

Ceftriaxoneb

0.008/0.047/

100

100

100

NA

NA

NA

0

0

0

<0.002-0.125

Cefiximeb

0.023/0.047/

100

100

97.5

NA

NA

NA

0

0

2.5

<0.016-0.25

Azithromycinb

0.19/0.38/

65

83.3

90

23

15.3

10

12

1.3

0

0.032-1

Ciprofloxacinb

0.006/6/

64

79

72

1

0

0

35

21

28

0.003- >32

Tetracyclineb

0.38/24/

56

56

55

8

9

5

36

35

40

0.094-24

Spectinomycinb

12/16/3-16

100

100

100

NA

NA

NA

0

0

0

Gentamicinc

2010-2011:

2012:

2013:

MIC range: 0.25-16 mg/L; MIC50: 2 mg/L; MIC90: 4 mg/L

MIC range: 2-16 mg/L; MIC50: 4 mg/L; MIC90: 8 mg/L

MIC range: 3-12 mg/L; MIC50: 6 mg/L; MIC90: 8 mg/L

  1. MIC50, minimum inhibitory concentration of 50% of isolates; MIC90, minimum inhibitory concentration of 90% of isolates; −, Not tested; NA, not applicable.
  2. aDue to the few isolates obtained in 2011, isolates from 2010 (n=72) and 2011 (n=6) were evaluated as one time point.
  3. bBreakpoints for susceptible and resistant isolates were according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST; www.eucast.org/clinical_breakpoints).
  4. cBreakpoints not stated by any organization.